Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
IRVINE, Calif., Aug. 28, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE:EVHC). Investors who purchased or otherwise acquired shares between March 2, 2015 and July 21, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 3, 2017 lead plaintiff motion deadline.
If you purchased shares of Envision during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Envision made materially false and/or misleading statements, and/or failed to disclose material information, to investors. On July 24, 2017, The New York Times reported that hospitals associated with the Company’s subsidiary, EmCare Holdings, Inc., were disproportionately likely to engage in “surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and subsequently billed at higher rates. When this information reached the public, shares of Envision dropped in value materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
